{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-148851","form_type":"8-K","ticker":"NEOG","cik":"0000711377","company_name":"NEOGEN CORP","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.665645+00:00","generated_at":"2026-05-15T06:50:57.826691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neogen Q3 FY26 revenue $211.2M; net loss $17M; divests Genomics unit","bullets":["Revenue $211.2M; Food Safety core growth +4.0%, Animal Safety core growth –8.7% on supplier challenges.","GAAP net loss $17.0M ($0.08 loss per share); Adjusted EPS $0.09; Adjusted EBITDA $48.2M (22.8% margin).","Divestiture of Genomics business announced, expected to close in Q2 FY27; proceeds to reduce leverage.","Raising FY2026 revenue outlook; maintaining Adjusted EBITDA guidance.","Petrifilm manufacturing transition on track for November FY27; validation on multiple SKUs started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-148851","json":"https://secwatch.observer/filing/0001193125-26-148851.json","markdown":"https://secwatch.observer/filing/0001193125-26-148851.md","text":"https://secwatch.observer/filing/0001193125-26-148851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711377/000119312526148851/0001193125-26-148851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711377/000119312526148851/neog-20260409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:50:57.826691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65d5761413622d67d324014e8086cd5d81b893d0","claim":"NEOGEN CORP reported third quarter ended February 28, 2026 results: revenue $211.2 million, net income Net loss of $17.0 million, EPS GAAP EPS of $(0.08). Guidance raised.","evidence_excerpt":"language in the filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Neogen Reports Third Quarter Fiscal Year 2026 Financial Results • Fiscal third quarter 2026 revenue of $211.2 million • Food Safety revenue growth of 2.6%, Core Growth 1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth 1 of (8.7%) due primarily to third-party supplier challenges in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711377/000119312526148851/0001193125-26-148851-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended February 28, 2026"},{"label":"Revenue","value":"$211.2 million"},{"label":"Net income","value":"Net loss of $17.0 million"},{"label":"EPS","value":"GAAP EPS of $(0.08)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}